Vertex Pharmaceuticals (NASDAQ:VRTX) Director Sangeeta Bhatia Sells 271 Shares of Company Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) Director Sangeeta Bhatia sold 271 shares of the stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $547.86, for a total transaction of $148,470.06. Following the transaction, the director directly owned 4,653 shares in the company, valued at approximately $2,549,192.58. This represents a 5.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vertex Pharmaceuticals Trading Up 0.4%

Shares of VRTX traded up $2.25 during mid-day trading on Wednesday, reaching $536.45. The company had a trading volume of 1,289,138 shares, compared to its average volume of 1,392,333. The stock has a market cap of $136.01 billion, a price-to-earnings ratio of 34.52, a price-to-earnings-growth ratio of 2.85 and a beta of 0.28. The firm has a fifty day simple moving average of $522.31 and a 200-day simple moving average of $484.43. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $412.27 and a fifty-two week high of $568.67. The company has a current ratio of 2.34, a quick ratio of 1.89 and a debt-to-equity ratio of 0.17.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 EPS for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06). The firm had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.42 billion. Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. The company’s quarterly revenue was up 11.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $4.80 earnings per share. On average, sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post 16.10 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on VRTX. Rothschild & Co Redburn increased their price target on Vertex Pharmaceuticals from $570.00 to $580.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Wall Street Zen downgraded Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, October 31st. Evercore increased their target price on Vertex Pharmaceuticals from $535.00 to $600.00 and gave the company an “outperform” rating in a research note on Wednesday, September 2nd. Morgan Stanley dropped their target price on Vertex Pharmaceuticals from $665.00 to $660.00 and set an “overweight” rating on the stock in a report on Tuesday, November 3rd. Finally, UBS Group lifted their price objective on shares of Vertex Pharmaceuticals from $615.00 to $640.00 and gave the company a “buy” rating in a research note on Tuesday, November 3rd. One analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $596.44.

Get Our Latest Stock Report on VRTX

Latest Vertex Pharmaceuticals News

These are some of the VRTX news items that stood out recently:

  • Positive Sentiment: Genomics extended its drug-target discovery and validation collaboration with Vertex by four years, building on a partnership that began in 2018. The extension supports Vertex’s ongoing research and pipeline development, though financial terms were not disclosed. Article: Genomics extends collaboration with Vertex
  • Neutral Sentiment: Investors are focused on Vertex’s late-stage pipeline and a U.S. regulatory decision expected November 30 for kidney drug povetacicept. The outcome could provide a meaningful catalyst, but uncertainty remains ahead of the decision. Article: Vertex pipeline and valuation outlook
  • Negative Sentiment: Multiple insiders reported sales: EVP Charles Wagner sold 15,286 shares, and directors Sangeeta N. Bhatia and Nancy Thornberry sold 271 and 1,000 shares, respectively. The sales could raise concern about insider sentiment, although all were conducted under pre-arranged Rule 10b5-1 plans, which can make them less informative as a signal about near-term prospects. Article: Vertex insider sales SEC filing: Sangeeta N. Bhatia SEC filing: Nancy Thornberry

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of VRTX. Summit Global Investments purchased a new stake in Vertex Pharmaceuticals in the second quarter worth $3,568,000. Danica Pension Livsforsikringsaktieselskab bought a new position in Vertex Pharmaceuticals during the 2nd quarter valued at approximately $13,823,000. UNIVEST FINANCIAL Corp bought a new position in Vertex Pharmaceuticals in the 2nd quarter worth about $4,495,000. State Street Corp boosted its stake in Vertex Pharmaceuticals by 1.2% during the 2nd quarter. State Street Corp now owns 11,871,459 shares of the pharmaceutical company’s stock valued at $5,896,910,000 after purchasing an additional 141,320 shares during the last quarter. Finally, Meeder Advisory Services Inc. bought a new stake in Vertex Pharmaceuticals in the 2nd quarter worth about $3,187,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Company Profile

(Get Free Report)

Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.

See Also

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.